Rentabilitas dodolan miturut bathi resik Xenetic Biosciences, Inc. (XBIO)

XBIO (xeneticbio.com) - tandha merek perusahaan

Xenetic Biosciences (XBIO) automates the creation of oncology drugs through robotic small-molecule screening. The net profit margin illustrates management efficiency, where the -123.70 mark reflects the latest data. The asset remains independent of macroeconomic trends, as demand for treatment is constant. Currently, Xenetic Biosciences is focusing on R&D, developing the XCART platform for B-cell lymphoma therapy.

xeneticbio.com (XBIO) - Margin dodolan perusahaan saka 04.07.2022 nganti 20.11.2026

xeneticbio.com (XBIO) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Produk dadi Xenetic Biosciences

A defensive portfolio requires rigorous screening of an asset's ability to generate a net residual from every dollar of revenue. This metric measures the share of final profit within total turnover, determining the business's actual margin of safety. For Xenetic Biosciences (XBIO), at the preclinical research stage of DNase, this metric reflects the efficiency of R&D cost management. The trend in net turnover profitability allows for an assessment of the company's financial stability within the laboratory cycle.

Pesaing Xenetic Biosciences (XBIO)

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik KAPA|Margin dodolan perusahaan OnKure Therapeutics, Inc.|Margin dodolan resik GDTC (w2.cytomed.sg)|CRIS - Rentabilitas dodolan miturut bathi resik|Apollomics - Margin dodolan resik|Tharimmune Corp (THAR) - Rentabilitas dodolan miturut bathi resik|ADVB: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Margin dodolan resik|Rentabilitas dodolan resik SBFM (Sunshine Biopharma)|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)